AusBiotech

Opal Biosciences has called for expressions of interest from companies and organisations wishing to support and/or participate in the formation of a Victorian Life Sciences and Biotechnology Development and Manufacturing Precinct.

Telix Pharmaceuticals (ASX:TLX) says a first patient has been dosed in a phase one study of TLX250-CDx ( 89Zr-DFO-girentuximab) in patients with urothelial carcinoma or bladder cancer at Fiona Stanley Hospital in Perth.

Antisense Therapeutics (ASX:ANP) has announced that it has received feedback on the Paediatric Investigation Plan for the development of ATL1102 for Duchenne muscular dystrophy from the Paediatric Committee of the European Medicines Agency.

Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the grant of patents by the respective agencies of the US and India for the manufacturing process for paxalisib.

In collaboration with AusBiotech and BioMelbourne Network, mRNA Victoria is seeking Victorian-based companies with relevant experience in mRNA or RNA-related manufacture, supply chain and systems support to submit their expression of interest for its Industry Panel.

Responding to advances in science, revised Guidelines for Stem Cell Research and Clinical Translation have been published by the International Society for Stem Cell Research.

Pfizer’s Centers for Therapeutic Innovation has entered a new oncology-focused research collaboration with the Melbourne-based St Vincent’s Institute of Medical Research.

Australian immunotherapy company Immutep (ASX:IMM) has announced a $60 million capital raise and approval for a phase one clinical trial of its lead investigative candidate as part of a triple combination for the treatment of various forms of solid tumour.

Australian regenerative medicine company Orthocell (ASX:OCC) has announced the first interim data of all patients in the CelGro nerve regeneration trial at 12 months post-treatment.

SUDA Pharmaceuticals (ASX:SUD) has announced it has signed a global, exclusive agreement with Imperial College London for a novel invariant Natural Killer T cell therapy platform.

Australian company Starpharma (ASX:SPL) has announced that the sale of its COVID-19 nasal spray in the UK has been temporarily halted following correspondence from this UK regulator related to promotional claims.

ENA Respiratory, a biotechnology company developing a nasal spray for the prevention of COVID-19 and other respiratory viral infections, has secured up to $32 million in a capital raise.